Navigation Links
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Date:5/5/2008

WOODCLIFF LAKE, N.J., May 5 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of Eisai Co., Ltd.

Ms. Schwalm brings to Eisai Inc. a strong track record of building high-performing organizations that drive global growth and nearly 25 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. She will report to Lonnel Coats, President & COO, Eisai Corporation of North America. Previously, Mr. Coats held dual responsibilities, also serving as President & COO of Eisai Inc.

"Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutical company," said Mr. Coats. "Ms. Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

Ms. Schwalm joins Eisai from Amgen, Inc., where over the course of her five-year tenure she rose to Vice President and General Manager of the U.S. Oncology Business Unit, a group with annual revenues exceeding $5 billion. In this role she led the 500-person business unit, oversaw all oncology strategy and served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, and health economic functions.

Prior to Amgen, Inc., Ms. Schwalm grew her pharmaceutical career over an 18-year period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. During this
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
2. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
3. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
4. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. BioElectronics Corporation Receives Major Orders From Italian Distributor
7. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
10. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... there was a monopoly phone service prior to the 1984 ... exclusivity in the territory and we will provide universal service ... a geographic subscriber base, the traditional phone companies ensured that ... fair price. There was one price across the board. That ...
... - Does the Wisconsin Alumni Research Foundation's ... for approval? , ,The foundation's stem cell patent is ... it is overly broad and is suppressing scientific research. ... the more than 300 academic licenses it has issued ...
... to clarify the definition of records for the treatment ... incorporate them into Electronic Health Records, has been signed ... 650 creates an exception to current law pertaining to ... to mental health records when they are treating patients ...
Cached Biology Technology:Does redefining universal service help bridge the digital divide? 2Does redefining universal service help bridge the digital divide? 3Does redefining universal service help bridge the digital divide? 4Does redefining universal service help bridge the digital divide? 5WARF stem cell patent faces long and winding road 2WARF stem cell patent faces long and winding road 3WARF stem cell patent faces long and winding road 4WARF stem cell patent faces long and winding road 5
(Date:7/9/2014)... by researchers at the NIH,s National Center ... collaborators to treat sickle cell disease has ... The drug candidate, Aes-103, is the first ... mechanism of sickle cell disease. Baxter now ... for regulatory approval and commercialization. , Sickle ...
(Date:7/9/2014)... protect neuronal function and increase the survival rate ... her team, School of Pharmaceutical Sciences, Southwest University, ... mice were administered with low dose of levothyroxine ... aged rats exhibited an obvious improvement in cognitive ... to 93%. The underlying mechanism was demonstrated that ...
(Date:7/9/2014)... less fit in terms of cardiorespiratory capacity, strength ... southern adolescents are more obese and present higher ... from the centre-north of Europe. , These are ... study conducted by scientists from the University of ... 25 other European research groups. The study compared ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2
... delivers new insight about rapid toxin evolution in venomous snakes: ... race with opossums, a group of snake-eating American marsupials. Although ... this fact has not been factored into previous explanations for ... usually seen as a feeding, or trophic, adaptation. But new ...
... contrast agents that sneak into bacteria disguised as glucose ... sensitivity and specificity. These agents -- called maltodextrin-based imaging ... other inflammatory conditions. "These contrast agents fill the ... of bacteria in vivo and distinguish infections from other ...
... 18, 2011) Researchers from the John Theurer Cancer ... 14 cancer-related studies during the recently concluded American Society ... June 3 7, 2011 in Chicago. The studies ... treatment outcomes, and patient quality of life issues. ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3New contrast agents detect bacterial infections with high sensitivity and specificity 2New contrast agents detect bacterial infections with high sensitivity and specificity 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6
... Escherichia coli RY 13 5'G AATTC3' 3'CTTAA G5' ... min or ethanol precipitation. Storage Conditions: 10mM Tris-HCl ... 0.15% Triton X-100, 0.01% BSA, 50% glycerol. Shipping ... -20C. Unit Definition: One unit is defined as ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
... Heavy duty stainless-steel shaker flask clips, purpose-designed ... speeds. All clips are equipped with ... 1L.) also include a bottom retainer spring, ... scratching of expensive glassware. Clips include ...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
Biology Products: